



Susan Mosier, MD, Secretary  
Michael Randol, Director

Department of Health & Environment

Sam Brownback, Governor

**Preferred Drug List Committee  
Meeting Agenda, Open Session  
September 13, 2017 10:00 am- 2:00 pm**

**Meeting Location**

DXC Technology (formerly HP Enterprise Services) Capital Room  
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

**Board Members**

Taylor Gill, PharmD., BCPS  
Wayne Wallace, M.D.  
Raymond Magee, M.D.  
Megan Hedden, PharmD.

Robert Haneke, PharmD  
Emily Prohaska, PharmD., BCACP  
Donna Sweet, M.D.

**KDHE-DHCF Staff**

Carol Arace

Annette Grant, RPh.  
Robert Handke, PharmD.

**DXC / HID Staff**

Karen Kluczykowski, RPh.

Ariane Casey, PharmD.

**I. Call to Order**

**A. Announcements**

**II. Old Business**

**A. Review and Approval of June 21, 2017 Meeting Minutes**

**B. PDL Organization - Dual Class Drug Placement**

- i. Proposed Amendment
  - 1. Justification provided by the state
- ii. Public Comment\*
- iii. Committee Discussion/Recommendations

### III. New Business

- A. Fluorouracil Agents – Topical – New Class: (Efudex®, Tolak®, Carac®, Fluoroplex®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- B. Rosacea Agents- Topical- New Class: (Azelex®, Finacea®, Mirvaso®, Soolantra®, Rhofade®, Metrocream®, Metrogel®, MetroLotion®, Noritate®, Rosadan®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- C. Hepatitis C Retreatment- New Class: (Vosevi®, Mavyret®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- D. Glucocorticoids- High Potency Topical- New Class: (Clobex®, Clobex Spray®, Cordran®, Cormax Scalp Application®, Diprolene®, Diprolene AF®, Olux®, Olux-E®, Psorcon®, Temovate®, Temovate E®, Topicort®, Vanos®, Elocon®, Halog®, Sernivo®, Clobetasol Propionate E®, ApexiCon E®, Clodan®, Ultravate®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- E. Glucocorticoids- Intermediate Potency Topical- New Class: (Cloderm®, Cutivate®, Luxiq®, Cordran®, Elocon®, Kenalog®, Synalar®, Westcort®, Capex®, Dermatop®, DesOwen®, Locoid®, Locoid LipoCream®, Pandel®, Nolix®, Triderm®, Derasorb TA®, Trianex®, Dermazone®, Tridesilon®, LoKara®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- F. Glucocorticoids- Mild Potency Topical - New Class: (Aclovate®, Derma-Smooth/FS Body & Scalp®, Fluocinolone Body and Scalp®, Desonate®, Verdeso®, Ala-Cort®, First-Hydrocortisone®, Derasorb HC®, Pediaderm HC®, Ala Scalp®, NuCort®, Texacort®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- G. Hepatitis C Antiviral Agents- Class Review, New Agent: Mavyret®
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- H. Androgenic Agents – Class Rename & New Agents: (Depo-Testosterone®, Striant®, Testred®, First-Testosterone MC®, Natesto®, Aveed®, Androxy®, Oxandrin®, Methitest®, Android®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations
- I. Immunomodulation Agents- Plaque Psoriasis- Class Review, New Agent: (Tremfya®)
  - i. Public Comment\*
  - ii. Committee Discussion/Recommendations

J. Immunomodulation Agents- Psoriatic Arthritis- Class Review, New Agent : (Orencia®)

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

K. Hereditary Angioedema Agents- Class Review, New Agent: (Haegarda®)

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

L. SGLT2 Inhibitors- Class Review, New Agent: (Xigduo XR®)

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

M. Inhaled Corticosteroids- Class Review- New Agent: (QVAR RediHaler®)

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

N. Anaphylaxis Agents- Class Review- New Agent: (Symjepi®)

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

O. Pre-approval for drug molecule dose form, dose device, IR/ER of current PDL drug

- i. Public Comment\*
- ii. Committee Discussion/Recommendations

P. Review of Previous Placement- Removal of Qtern® from DPP-4 Inhibitor Class

- i. See decision on II B Old Business
- ii. Public Comment\*
- iii. Committee Discussion/Recommendations

Q. Review of Previous Placement- Removal of Glyxambi® from DPP-4 Inhibitor Class

- i. See decision on II B Old Business
- ii. Public Comment\*
- iii. Committee Discussion/Recommendations

IV. Open Public Comment

V. Adjourn

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***